ABSTRACT
BACKGROUND
Recent and national data on adherence to heart failure drugs are limited, particularly among the disabled and some small minority groups, such as Native Americans and Hispanics.
OBJECTIVE
We compare medication adherence among Medicare patients with heart failure, by disability status, race/ethnicity, and income.
DESIGN
Observational study.
SETTING
US Medicare Parts A, B, and D data, 5 % random sample, 2007–2009.
PARTICIPANTS
149,893 elderly Medicare beneficiaries and 21,204 disabled non-elderly beneficiaries.
MAIN MEASURES
We examined 5 % of Medicare fee-for-service beneficiaries with heart failure in 2007–2009. The main outcome was 1-year adherence to one of three therapeutic classes: β-blockers, diuretics, and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs). Adherence was defined as having prescriptions in possession for ≥ 75 % of days.
KEY RESULTS
Among aged beneficiaries, 1-year adherences to at least one heart failure drug were 63 %, 57 %, 53 %, 50 %, and 52 % for Whites, Asians, Hispanics, Native Americans and Blacks, respectively; among the disabled, 1-year adherence was worse for each group: 57 %, 53 %, 48 %, 44 % and 43 % respectively. The racial/ethnic difference persisted after adjustment for age, gender, income, drug coverage, location and health status. Patterns of adherence were similar among beneficiaries on all three therapeutic classes. Among beneficiaries with close-to-full drug coverage, minorities were still less likely to adhere relative to Whites, OR = 0.61 (95 % CI 0.58–0.64) for Hispanics, OR = 0.59 (95 % CI 0.57–0.62) for Blacks and OR = 0.57 (95 % CI 0.47–0.68) for Native Americans.
CONCLUSION
After the implementation of Medicare Part D, adherence to heart failure drugs remains problematic, especially among disabled and minority beneficiaries, including Native Americans, Blacks, and Hispanics. Even among those with close-to-full drug coverage, racial differences remain, suggesting that policies simply relying on cost reduction cannot eliminate racial differences.
Similar content being viewed by others
REFERENCES
American Heart Association. Heart and Stroke Statistical Update. Dallas: American Heart Association 2006; 2006.
Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977–2016. doi:10.1161/circulationaha.109.192064.
Wu J-R, Moser DK, Chung ML, Lennie TA. Objectively measured, but not self-reported, medication adherence independently predicts event-free survival in patients with heart failure. J Card Fail. 2008;14(3):203–10.
Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80 %. BMJ. 2003;326(7404):1419.
Newby LK, Allen LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203–12. doi:10.1161/circulationaha.105.505636.
Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088–97. doi:10.1056/NEJMsa1107913.
Stroupe KT, Teal EY, Weiner M, Gradus-Pizlo I, Brater DC, Murray MD. Health care and medication costs and use among older adults with heart failure. Am J Med. 2004;116(7):443–50.
Zhang Y, Wu S, Fendrick AM, Baicker K. Variation in medication adherence in heart failure. JAMA Intern Med. 2013:1–2. doi:10.1001/jamainternmed.2013.2509
Neuman P, Strollo MK, Guterman S, et al. Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors. Health Aff. 2007;26(5):w630–43. doi:10.1377/hlthaff.26.5.w630.
Zhang Y, Lave JR, Donohue JM, Fischer MA, Chernew ME, Newhouse JP. The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products. Med Care. 2010;48(5):409–17. doi:10.1097/MLR.0b013e3181d68978.
Institute of Medicine. Geographic Variation in Health Care Spending and Promotion of High-Value Care - Interim Report. IOM. 2013. http://www.iom.edu/Reports/2013/Geographic-Variation-in-Health-Care-Spending-and-Promotion-of-High-Care-Value-Interim-Report.aspx. Accessed October 21, 2013.
Bonito A, Bann C, Eicheldinger C, Carpenter L. Creation of new race-ethnicity codes and Socioeconomic Status (SES) indicators for medicare beneficiaries. Final Report. Sub-Task 2. (Prepared by RTI International for the Centers for Medicare and Medicaid Services through an interagency agreement with the Agency for Healthcare Research and Policy, under Contract No. 500-00-0024, Task No. 21). Agency for Healthcare Research and Quality, Rockville, MD. 2008. http://www.ahrq.gov/qual/medicareindicators/medicareindicators.pdf. Accessed October 21, 2013.
Zhang Y, Baik SH, Chang CC, Kaplan CM, Lave JR. Disability, race/ethnicity, and medication adherence among Medicare myocardial infarction survivors. Am Heart J. 2012;164(3):425–33 e4. doi:10.1016/j.ahj.2012.05.021.
Kaiser Family Foundation. Low-income assistance under the Medicare drug benefit. Menlo Park, CA, USA. 2009. http://kaiserfamilyfoundation.files.wordpress.com/2013/01/7327-05.pdf. Accessed October 21, 2013.
Zhang Y, Baik SH, Fendrick AM, Baicker K. Comparing local and regional variation in health care spending. N Engl J Med. 2012;367(18):1724–31. doi:10.1056/NEJMsa1203980.
Centers for Medicare & Medicaid Services. 2011 Model diagnosis and model softweare—RxHCC model software. Centers for Medicare & Medicaid Services, Baltimore, MD, USA. 2011. https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Risk_adjustment.html. Accessed October 21, 2013.
Davis AM, Vinci LM, Okwuosa TM, Chase AR, Huang ES. Cardiovascular health disparities: a systematic review of health care interventions. Med Care Res Rev. 2007;64(5 Suppl):29S–100S.
Lewey J, Shrank WH, Bowry AD, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J. 2013;165(5):665–78 e1. doi:10.1016/j.ahj.2013.02.011.
Bagchi AD, Esposito D, Kim M, Verdier J, Bencio D. Utilization of, and adherence to, drug therapy among Medicaid beneficiaries with congestive heart failure. Clin Ther. 2007;29(8):1771–83.
Zhang Y, Gellad WF, Zhou L, Lin Y-J, Lave JR. Access to and use of $4 Generic Programs in Medicare. J Gen Intern Med. 2012;27(10):1251–7.
Wijeysundera HC, Machado M, Farahati F, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994–2005. JAMA. 2010;303(18):1841–7.
Zhang Y, Donohue JM, Lave JR, O’Donnell G, Newhouse JP. The effect of Medicare Part D on drug and medical spending. N Engl J Med. 2009;361(1):52–61. doi:10.1056/NEJMsa0807998.
Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354(22):2349–59.
Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555–67.
Acknowledgements
We gratefully acknowledge funding from the Institute of Medicine, National Institute of Mental Health (No. RC1 MH088510) and Agency for Healthcare Research and Quality (No. R01 HS018657) to Dr. Zhang.
Role of the Sponsor
Sponsors played no role in the study conduct, data analysis, or report generation.
Conflict of Interest
The authors declare that they do not have a conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
Rights and permissions
About this article
Cite this article
Zhang, Y., Baik, S.H. Race/Ethnicity, Disability, and Medication Adherence Among Medicare Beneficiaries with Heart Failure. J GEN INTERN MED 29, 602–607 (2014). https://doi.org/10.1007/s11606-013-2692-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11606-013-2692-x